• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Carboxylic acid derivatives Carboxylic acid amides
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Introduction to 1H-Pyrazole-3,5-dicarboxamide (CAS No. 1397683-79-2)

1H-Pyrazole-3,5-dicarboxamide, identified by its Chemical Abstracts Service (CAS) number 1397683-79-2, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry due to its versatile structural framework and potential biological activities. The pyrazole core, a five-membered aromatic ring containing two nitrogen atoms, is a privileged scaffold in drug discovery, known for its ability to modulate various biological pathways. The introduction of carboxamide functionalities at the 3 and 5 positions enhances the compound's pharmacological profile, making it a promising candidate for further exploration.

The structural motif of 1H-Pyrazole-3,5-dicarboxamide imparts unique electronic and steric properties that can be exploited in the design of novel therapeutic agents. The presence of two carboxamide groups not only increases the compound's solubility in polar solvents but also provides multiple sites for hydrogen bonding interactions with biological targets. These features are particularly relevant in the development of small-molecule inhibitors targeting enzymes and receptors involved in metabolic diseases, inflammatory responses, and cancer.

Recent advancements in computational chemistry and molecular modeling have facilitated a deeper understanding of the interactions between 1H-Pyrazole-3,5-dicarboxamide and its potential targets. Studies have shown that the compound can engage in favorable binding interactions with proteins through its carboxamide moieties, which can be tailored to optimize affinity and selectivity. This has opened up new avenues for the development of targeted therapies against diseases such as diabetes, cardiovascular disorders, and neurodegenerative conditions.

In the realm of medicinal chemistry, 1H-Pyrazole-3,5-dicarboxamide has been explored as a precursor for synthesizing more complex derivatives with enhanced biological activity. Functional group modifications at the pyrazole ring and the carboxamide groups have led to the discovery of novel compounds with improved pharmacokinetic properties. For instance, derivatives of this scaffold have demonstrated promising results in preclinical studies as inhibitors of polyphenol oxidase enzymes, which play a crucial role in fruit ripening and food spoilage.

The synthesis of 1H-Pyrazole-3,5-dicarboxamide involves multi-step organic reactions that highlight the compound's synthetic versatility. The process typically begins with the condensation of hydrazine hydrate with diethyl oxalate to form pyrazole-3,5-dicarbonitrile, which is subsequently converted into the corresponding dicarboxylic acid. Further functionalization via amide bond formation yields the target compound. This synthetic route underscores the importance of 1H-Pyrazole-3,5-dicarboxamide as a key intermediate in pharmaceutical manufacturing.

One of the most compelling aspects of 1H-Pyrazole-3,5-dicarboxamide is its potential application in drug repurposing. Given its structural similarity to known bioactive molecules, computational screens have identified it as a candidate for repurposing against emerging infectious diseases. The compound's ability to modulate host-pathogen interactions makes it an attractive option for developing treatments against viruses and bacteria that have developed resistance to conventional antibiotics.

The pharmacological profile of 1H-Pyrazole-3,5-dicarboxamide has been further investigated through in vitro and in vivo assays. Initial studies have revealed its ability to inhibit the activity of certain kinases involved in cancer progression. The carboxamide groups serve as hydrogen bond donors and acceptors, allowing the compound to interact with key residues in the active sites of these enzymes. This interaction disrupts signaling pathways critical for tumor growth and metastasis.

Moreover, 1H-Pyrazole-3,5-dicarboxamide has shown promise in modulating inflammatory responses by interacting with cytokine receptors and downstream signaling molecules. Its structural features enable it to interfere with pro-inflammatory cascades without compromising host immune defenses. This makes it a potential therapeutic agent for chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The development of novel delivery systems has also been explored for 1H-Pyrazole-3,5-dicarboxamide, aiming to enhance its bioavailability and target specificity. Nanoparticle formulations encapsulating this compound have demonstrated improved delivery efficiency across biological barriers. These advancements are particularly relevant for treating neurological disorders where blood-brain barrier penetration is a significant challenge.

Future research directions for 1H-Pyrazole-3,5-dicarboxamide include exploring its role in epigenetic modulation. The pyrazole scaffold is known to interact with histone deacetylases (HDACs), enzymes that regulate gene expression by modifying chromatin structure. By inhibiting HDACs or modulating their activity, 1H-Pyrazole-3,5-dicarboxamide could potentially be used to treat epigenetic disorders such as cancer and neurodegenerative diseases.

In conclusion,1H-Pyrazole-3,5-dicarboxamide (CAS No. 1397683-79-2) represents a fascinating example of how structural innovation can lead to novel therapeutic opportunities. Its versatile pharmacological profile and synthetic accessibility make it an attractive candidate for further development in drug discovery programs targeting a wide range of diseases.

• 76312-30-6(1H-Pyrazole-3-carboxylic acid, 5-methyl-, 2-methylhydrazide)
• 40535-14-6(5-methyl-1H-pyrazole-3-carbohydrazide)
• 33064-36-7(1H-Pyrazole-3-carboxamide)
• 4027-55-8(5-Methyl-1H-pyrazole-3-carboxamide)
• 71083-83-5(5-(Hydroxymethyl)-1H-pyrazole-3-carboxamide)
• 88393-96-8(6-Methylpyridazine-3-carboxamide)
• 14671-10-4(3-Methyl-1H-pyrazole-5-carboxamide)
• 37027-00-2( )
• 89270-44-0(1H-Pyrazole-3-carboxamide,N-hydroxy-5-methyl-)
• 4027-56-9(5-Methyl-1H-pyrazole-3-carboxamide)